You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

pyrotinib

Showing 26 - 50 of 62
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Lapatinib Resistant HER2-Positive Metastatic Breast Cancer

Active, not recruiting
  • Breast Cancer
  • Pyrotinib
  • Nanjing, Jiangsu, China
    Jiangsu Provincial People's Hospital
May 19, 2021

Breast Cancer Trial in Shanghai (Pyrotinib, Placebo)

Active, not recruiting
  • Breast Cancer
  • Pyrotinib
  • Placebo
  • Shanghai, China
    Fudan University Cancer Hospital
May 20, 2021

Metastatic Breast Cancer Trial in Shanghai (Trastuzumab, pyrotinib, Dalpiciclib)

Not yet recruiting
  • Metastatic Breast Cancer
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center Shanghai, China, 200032
Oct 11, 2022

Breast Cancer Trial in Shenyang (Pyrotinib, Trastuzumab)

Not yet recruiting
  • Breast Cancer
  • Shenyang, Liaoning, China
    Shengjing Hospital affiliated to China Medical University
Jul 13, 2021

Breast Cancer Trial in Nanjing (Pyrotinib, Trastuzumab, Pertuzumab)

Recruiting
  • Breast Cancer
  • Pyrotinib
  • +5 more
  • Nanjing, Jiangsu, China
    the First Affiliated Hospital of Nanjing Medical University
Jun 2, 2021

Breast Cancer, Metastatic Cancer Trial in Shanghai (SHR7390, Famitinib, SHR3162)

Recruiting
  • Breast Cancer
  • Metastatic Cancer
  • Shanghai, Shanghai, China
    Cancer Hospital Affiliated to Fudan University
Jul 22, 2022

Breast Cancer, Hormone-receptor Positive Breast Cancer Trial in Guangzhou (Pyrotinib, Epirubicin, Doxorubicin Hydrochloride

Recruiting
  • Breast Cancer
  • Hormone-receptor Positive Breast Cancer
  • Pyrotinib
  • +6 more
  • Guangzhou, Guangdong, China
    Sun-Yat-Sen Memorial Hospital of Sun-Yat-Sen University
Apr 29, 2021

18F-FDG Uptake Heterogeneity Predicts Pyrotinib Response

Completed
  • HER2-positive Breast Cancer
  • Pyrotinib
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Feb 12, 2021

HER2+ Breast Cancer Trial in Xi'an (Trastuzumab, Pertuzumab, Nab paclitaxel)

Recruiting
  • HER2+ Breast Cancer
  • Xi'an, Shaanxi, China
  • +1 more
Jun 20, 2022

HER2-positive Breast Cancer Trial in China (Pyrotinib, Placebo Oral Tablet, Trastuzumab)

Active, not recruiting
  • HER2-positive Breast Cancer
  • Pyrotinib
  • +3 more
  • Beijing, Beijing, China
  • +16 more
Aug 3, 2021

Breast Tumor, Breast Cancer, Breast Tumors Trial in Shanghai (Dalpiciclib, Pyrotinib, SHR-A1811)

Not yet recruiting
  • Breast Neoplasm
  • +9 more
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center Shanghai, China, 200032
Oct 13, 2022

Breast Cancer Trial in Guangzhou (Inetetamab, Pyrotinib, Capecitabine)

Recruiting
  • Breast Cancer
  • Guangzhou, Guangdong, China
    Sun Yat Sen Memorial Hospital，Sun Yat sen University
Dec 18, 2020

Salivary Gland Tumors Trial in Shanghai (Pyrotinib, Bicalutamide, Leuprorelin)

Recruiting
  • Salivary Gland Neoplasms
  • Pyrotinib
  • +2 more
  • Shanghai, Shanghai, China
    Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Ton
Oct 8, 2021

Breast Cancer, Gastric Cancer, Solid Tumors Trial in United States (Pyrotinib)

Unknown status
  • Breast Cancer
  • +3 more
  • Pyrotinib
  • Orange, California
  • +9 more
Jan 28, 2021

Breast Cancer Trial in Beijing (Inetetamab, Rapamycin, Pyrotinib)

Not yet recruiting
  • Breast Cancer
  • Beijing, China
    National Cancer Center/National Clinical Research Center for Can
Jan 31, 2021

Breast Cancer Trial in Shanghai (Pyrotinib, nab-Paclitaxel, Trastuzumab)

Terminated
  • Breast Cancer
  • Pyrotinib
  • +4 more
  • Shanghai, Shanghai, China
    Ruijin Hospital, Shanghai Jiaotong University School of Medicine
May 16, 2020

Eribulin in the Treatment of Advanced Breast Cancer

Recruiting
  • Breast Cancer
  • Guangzhou, Guangdong, China
    Sun Yat Sen Memorial Hospital，Sun Yat sen University
Dec 19, 2020

Breast Cancer Trial (Pyrotinib, Epirubicin, Cyclophosphamide)

Not yet recruiting
  • Breast Cancer
  • Pyrotinib
  • +4 more
  • (no location specified)
Feb 27, 2020

Breast Cancer Trial in Guangzhou (Pyrotinib)

Not yet recruiting
  • Breast Cancer
  • Pyrotinib
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Feb 5, 2020

Non-squamous NSCLC, HER2 Exon 20 Mutation Trial in Worldwide (Pyrotinib, Docetaxel)

Recruiting
  • Non-squamous NSCLC
  • HER2 Exon 20 Mutation
  • Orange, California
  • +102 more
Oct 18, 2021

Breast Cancer, HER2-positive Breast Cancer, ER-positive Breast Cancer Trial (SHR6390, Anastrozole, Pyrotinib)

Unknown status
  • Breast Cancer
  • +2 more
  • (no location specified)
Jan 17, 2020

Solid Tumor, HER2 Gene Mutation, HER-2 Gene Amplification Trial in Tianjin (Pyrotinib)

Not yet recruiting
  • Solid Tumor
  • +3 more
  • Pyrotinib
  • Tianjin, Tianjin, China
    Tianjin Medical University Second Hospital
Nov 25, 2019

HER2-positive Breast Cancer Trial (Pyrotinib, Trastuzumab)

Not yet recruiting
  • HER2-positive Breast Cancer
  • (no location specified)
Nov 7, 2019

Breast Cancer Female, HER2-positive Breast Cancer, Hormone Receptor Positive Malignant Tumor of Breast Trial in Fuzhou

Not yet recruiting
  • Breast Cancer Female
  • +5 more
  • Pyrotinib
  • +2 more
  • Fuzhou, Fujian, China
    Fuzhou general hospital
Sep 11, 2019

Metastatic Breast Cancer, HER2-positive Breast Cancer Trial in Jinan (Pyrotinib, SHR6390, Letrozole)

Unknown status
  • Metastatic Breast Cancer
  • HER2-positive Breast Cancer
  • Pyrotinib
  • +3 more
  • Jinan, China
    Breast Cancer Center, Shandong Cancer Hospital Affiliated to Sha
Sep 18, 2019